YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm's Analyst Current Favorites list feat…
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu…
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment. Continue Reading
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer. Continue Reading
[Cancer cells on human tissue. 3D illustration.] anusorn nakdee Tyra Biosciences (TYRA [https://seekingalpha.com/symbol/TYRA]) added more than 13% on Thursday, marking its best intraday rally since January, after scheduling a conference ca…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Wednesday. U.S. stock index futures rose on Wednesday as Wall Street looked to continue…
[Technology background image, graph, displaying analytical data about stock trading.] Donny DBM William Blair added Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), American Express (AXP [https://seekingalpha.com/symbol/AXP]), Ecolab…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list. TheFly reported on June 17 that Oppenheimer initiat…
The non-muscle invasive bladder cancer market is witnessing significant growth due to the rising global incidence of bladder cancer, advancements in immunotherapy, targeted treatments, and launch of novel therapies such as CG0070 (cretosti…
Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target.…
Key Points HighVista increased its Tyra Biosciences holding by 96,218 shares in the first quarter; the estimated trade size was $3.11 million (based on quarterly average prices). The quarter-end position value rose by $4.11 million, reflec…
On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, High…
* Tyra Biosciences press release [https://seekingalpha.com/pr/20513089-tyra-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights] (TYRA [https://seekingalpha.com/symbol/TYRA]): Q1 GAAP EPS of -$0.64. * Cash, Cash…
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Tyra Biosciences, Inc. is one of the best biotech stocks on this list. TheFly reported on April 15 that Guggenheim Securities initiated coverage of TYRA…
On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone C…
On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SEC)…
Nextech Invest, Ltd. disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it reduced its stake in Kymera Therapeutics(NASDAQ:KYMR) by 62,013 shares, an estimated $4.19 million trade based on quarterly aver…
5AM Venture Management disclosed a full exit from Dianthus Therapeutics(NASDAQ:DNTH) on February 17, 2026, selling 365,053 shares worth $14.36 million in the fourth quarter. What happened According to a Securities and Exchange Commission (…
Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position…
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines(NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values. What happened According to a Securities an…
Key Points Commodore Capital sold 2,338,287 shares of Agios Pharmaceuticals in the fourth quarter. The quarter-end position value declined by $93.86 million as a result. The position, which was previously 4.6% of the fund's AUM, was wiped…
On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals(NASDAQ:AGIO) in the fourth quarter, an estimated $93.86 million transact…
On February 17, 2026, Commodore Capital disclosed in an SEC filing that it sold out its entire 3,200,000-share position in Viridian Therapeutics (NASDAQ:VRDN), an estimated $69.06 million transaction based on last-disclosed position values…
Commodore Capital disclosed a buy of 400,161 shares of Spyre Therapeutics(NASDAQ:SYRE), an estimated $10.46 million trade based on quarterly average pricing, per a February 17, 2026, SEC filing. What happened According to a February 17, 20…
Commodore Capital reduced its stake in Centessa Pharmaceuticals(NASDAQ:CNTA) by 1,850,000 shares in the fourth quarter, according to a February 17, 2026, SEC filing. The estimated transaction value, based on quarterly average pricing, was…
Commodore Capital reported a sale of 850,000 shares of Nuvalent(NASDAQ:NUVL) in its latest SEC filing dated February 17, 2026, with the estimated transaction value at $83.81 million based on quarterly average pricing. What happened Accordi…
Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratini…
Key Points Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. The director still owns nearly 4 million shares, worth approximately $77.6 million. The stock is up more than 80% year to date, bu…
Key Points Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. The director still owns nearly 4 million shares, worth approximately $77.6 million. The stock is up more than 80% year to date, bu…
Once dear to the investing community like artificial intelligence is nowadays, stocks in the biotech space do not grab as much attention these days. Damning incidents of data breaches at companies like 23andMe (MEHCQ) and fraud against the…
(RTTNews) - Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several na…
* Tyra Biosciences press release [https://seekingalpha.com/pr/20201861-tyra-biosciences-reports-second-quarter-2025-financial-results-and-highlights] (NASDAQ:TYRA [https://seekingalpha.com/symbol/TYRA]): Q2 GAAP EPS of -$0.47. MORE ON TYRA…
Investing.com - H.C. Wainwright has reiterated its Buy rating and $30.00 price target on Tyra Biosciences (NASDAQ:TYRA), representing over 200% upside from the current price of $9.57, following the company’s announcement that the first pat…
-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported in 1H 2026- CARLSBAD, Calif., June 30, 2025 /PRNewswire/ -- Tyra Bio…
Tyra Biosciences , Inc. (NASDAQ:TYRA), a clinical-stage biotech company with a market capitalization of $484 million, announced Monday that it has dosed the first patient in its SURF302 Phase 2 clinical study of TYRA-300 for the treatment…
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug BofA Securities has upgraded Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company focused on devel…